--Smart Nasal Cannula: Big technology Change, Plus a New Product Launch Model for Oxyview --GSA Interest: Department of Interior protecting America's Natural Resources --Framework of Oxyview-Targeting Efficient Respiratory Consumption --A New Business Model for Smart Nasal Cannula Medical Technology --Multi-Media Presentations, Ingen website Oxyview Video Infomercial Sponsored by COPD Digest and COPD Foundation with Research Report from Grass Roots Research and Distribution Inc.
RIVERSIDE, Calif., June 10, 2013 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (OTC Pink:IGNT) announces its first purchase order from the U.S. Department of Interior under a GSA contract award.
Research report for Medical Division, along with analyst projections and presentations, are available at http://www.otcmarkets.com/financialReportViewer?symbol=IGNT&id=95782
Predictions from the Research:
Management is focused on making Ingen Technologies a world class organization in the $185.0 billion global medical device industry. The Company has initiated a national distribution program with the largest distributor of home health care products and services to establish itself in the $55.0 billion US home healthcare industry. The Company plans to aggressively market Oxyview® to VA Hospitals and Department of Defense military medical facilities. In addition to organic growth, the Company is expected to make several acquisitions of which one was recently announced, to expand its product portfolio.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.